Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Оптимизация тактики ведения пациенток с воспалительными заболеваниями органов малого таза
Оптимизация тактики ведения пациенток с воспалительными заболеваниями органов малого таза
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Воспалительные заболевания органов малого таза включают в себя большой спектр воспалительных процессов половых органов. Современная диагностика воспалительных заболеваний органов малого таза должна включать в себя использование всех высокоинформативных диагностических ресурсов и осознанное снижение диагностического порога.
Ключевые слова: ВЗОМТ, воспаление, диагностика.
Key words: PID, inflammation, diagnostics.
Ключевые слова: ВЗОМТ, воспаление, диагностика.
________________________________________________
Key words: PID, inflammation, diagnostics.
Полный текст
Список литературы
1. Гинекология: национальное руководство. Под ред. В.И.Кулакова, И.Б.Манухина, Г.М.Савельевой. М.: ГЭОТАР-Медиа, 2011; с. 704–24.
2. Blake DR. Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women. J Pediatr Adolesc Gynecol 2003; 16 (1): 25–30.
3. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 149 (16): 878–84.
4. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010; 21 (3): 195–7.
5. Bebear CM, Barbeyrac B, Pereyre S. Activity of moxifloxacin against theurogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801–5.
6. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: 12.
7. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
8. European guideline (IUSTI/WHO) for the management of STI 2010. http://www.iusti.org
9. Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.
10. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A): 143.
11. Hillis SD, Joesoef , Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 163: 1503–9.
12. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 2011: 753037.
13. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676–9.
14. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.
15. Lin HW, Tu YY, Lin SY. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900–4.
16. Pascual A, García I, Ballesta S. Uptake and intracellular activity of moxifloxacin in human neutrophiles and tissue-cultured epithelial cells. Antimicrob. Agents Chemother 1999; 43 (1): 12–5.
17. RCOG Green Top Guidelines – Management of Pelvic Inflammatory Disease (2003, 2009). www.rcog.org.uk
18. Ross JD, Cronjé HS, Paszkowski T, Rakoczi I. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multi-centers, double blind, randomized trial. Sex Transm Infect 2006; 82 (6): 446–51.
19. Solomkin J, Zhao YP, Ma EL. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.
20. Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132–6.
21. Stein GE, Schooley S, Tyrrell KL. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008; 14 (1): 8–12.
22. Sweet RL. Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management. Curr Infect Dis Rep 2012; 2.
2. Blake DR. Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women. J Pediatr Adolesc Gynecol 2003; 16 (1): 25–30.
3. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 149 (16): 878–84.
4. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010; 21 (3): 195–7.
5. Bebear CM, Barbeyrac B, Pereyre S. Activity of moxifloxacin against theurogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801–5.
6. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: 12.
7. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
8. European guideline (IUSTI/WHO) for the management of STI 2010. http://www.iusti.org
9. Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.
10. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A): 143.
11. Hillis SD, Joesoef , Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 163: 1503–9.
12. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 2011: 753037.
13. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676–9.
14. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.
15. Lin HW, Tu YY, Lin SY. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900–4.
16. Pascual A, García I, Ballesta S. Uptake and intracellular activity of moxifloxacin in human neutrophiles and tissue-cultured epithelial cells. Antimicrob. Agents Chemother 1999; 43 (1): 12–5.
17. RCOG Green Top Guidelines – Management of Pelvic Inflammatory Disease (2003, 2009). www.rcog.org.uk
18. Ross JD, Cronjé HS, Paszkowski T, Rakoczi I. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multi-centers, double blind, randomized trial. Sex Transm Infect 2006; 82 (6): 446–51.
19. Solomkin J, Zhao YP, Ma EL. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.
20. Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132–6.
21. Stein GE, Schooley S, Tyrrell KL. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008; 14 (1): 8–12.
22. Sweet RL. Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management. Curr Infect Dis Rep 2012; 2.
2. Blake DR. Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women. J Pediatr Adolesc Gynecol 2003; 16 (1): 25–30.
3. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 149 (16): 878–84.
4. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010; 21 (3): 195–7.
5. Bebear CM, Barbeyrac B, Pereyre S. Activity of moxifloxacin against theurogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801–5.
6. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: 12.
7. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
8. European guideline (IUSTI/WHO) for the management of STI 2010. http://www.iusti.org
9. Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.
10. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A): 143.
11. Hillis SD, Joesoef , Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 163: 1503–9.
12. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 2011: 753037.
13. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676–9.
14. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.
15. Lin HW, Tu YY, Lin SY. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900–4.
16. Pascual A, García I, Ballesta S. Uptake and intracellular activity of moxifloxacin in human neutrophiles and tissue-cultured epithelial cells. Antimicrob. Agents Chemother 1999; 43 (1): 12–5.
17. RCOG Green Top Guidelines – Management of Pelvic Inflammatory Disease (2003, 2009). www.rcog.org.uk
18. Ross JD, Cronjé HS, Paszkowski T, Rakoczi I. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multi-centers, double blind, randomized trial. Sex Transm Infect 2006; 82 (6): 446–51.
19. Solomkin J, Zhao YP, Ma EL. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.
20. Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132–6.
21. Stein GE, Schooley S, Tyrrell KL. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008; 14 (1): 8–12.
22. Sweet RL. Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management. Curr Infect Dis Rep 2012; 2.
________________________________________________
2. Blake DR. Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women. J Pediatr Adolesc Gynecol 2003; 16 (1): 25–30.
3. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 149 (16): 878–84.
4. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010; 21 (3): 195–7.
5. Bebear CM, Barbeyrac B, Pereyre S. Activity of moxifloxacin against theurogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801–5.
6. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: 12.
7. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
8. European guideline (IUSTI/WHO) for the management of STI 2010. http://www.iusti.org
9. Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.
10. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A): 143.
11. Hillis SD, Joesoef , Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 163: 1503–9.
12. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 2011: 753037.
13. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676–9.
14. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.
15. Lin HW, Tu YY, Lin SY. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900–4.
16. Pascual A, García I, Ballesta S. Uptake and intracellular activity of moxifloxacin in human neutrophiles and tissue-cultured epithelial cells. Antimicrob. Agents Chemother 1999; 43 (1): 12–5.
17. RCOG Green Top Guidelines – Management of Pelvic Inflammatory Disease (2003, 2009). www.rcog.org.uk
18. Ross JD, Cronjé HS, Paszkowski T, Rakoczi I. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multi-centers, double blind, randomized trial. Sex Transm Infect 2006; 82 (6): 446–51.
19. Solomkin J, Zhao YP, Ma EL. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.
20. Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132–6.
21. Stein GE, Schooley S, Tyrrell KL. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008; 14 (1): 8–12.
22. Sweet RL. Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management. Curr Infect Dis Rep 2012; 2.
Авторы
А.В.Шуршалина
Американский медицинский центр, Москва
Американский медицинский центр, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.